



SYNERGISTIC ANTHELMINTIC POTENTIAL OF ZINGIBER OFFICINALE (GINGER) AND ACORUS CALAMUS (SWEET FLAG): A COMPREHENSIVE REVIEW OF IN VITRO AND IN VIVO EVIDENCE, MECHANISMS OF ACTION, AND SAFETY CONSIDERATIONS

Mahesh Reddy, Tushar Matapathi, Rani Dagade, Sayali Navhale, Sanika Talekar,
Aditya Phatak, Ms. Shraddha Desai

Article DOI: <https://doi.org/10.36713/epra20893>

DOI No: 10.36713/epra20893

ABSTRACT

This review examines the synergistic anthelmintic potential of *Zingiber officinale* (ginger) and *Acorus calamus* (sweet flag). It summarizes the current literature on their combined use against parasitic worms, focusing on *in vitro* and *in vivo* studies. The potential mechanisms underlying their synergistic effects, such as enhanced inhibition of parasite neuromuscular function, disruption of tegument integrity, and modulation of host immune response, are discussed. The review also addresses the safety considerations of using these two plants in combination, with particular emphasis on the use of low β -asarone *A. calamus* chemotypes. Despite the limited research on their combined anthelmintic activity, this review highlights the promising potential of this plant combination for developing novel anti-parasitic therapies and emphasizes the need for further research to establish its efficacy, safety, and optimal usage.

KEYWORDS: *Zingiber officinale*, *Acorus calamus*, Ginger, Sweet Flag, Anthelmintic, Synergism, β -Asarone, Gingerols, Asarones, Parasitic Worms, Mechanism of Action, *In vitro*, *In vivo*

1. INTRODUCTION

Parasitic worm infections, also known as helminthiasis, represent a significant global health burden, affecting billions of people worldwide, particularly in tropical and subtropical regions [1]. These infections can cause a wide range of health problems, including malnutrition, anemia, developmental delays, and organ damage [2]. In livestock, helminth infections lead to substantial economic losses due to reduced productivity and treatment costs [3]. While conventional anthelmintic drugs are available, their efficacy is often hampered by the emergence of drug resistance, and some have undesirable side effects [4]. This has spurred a growing interest in exploring alternative and complementary therapies, including the use of medicinal plants. *Zingiber officinale* Roscoe (ginger), a member of the Zingiberaceae family, and *Acorus calamus* Linn. (sweet flag), belonging to the Acoraceae family, are two such plants with a long history of use in traditional medicine systems for treating various ailments, including parasitic infections [5]. Ginger, a widely used spice and condiment, has been shown to possess a broad spectrum of pharmacological activities, including anti-inflammatory, antioxidant, antiemetic, and anthelmintic properties [6]. Its major bioactive constituents include gingerols, shogaols, and various essential oil components [7]. *A. calamus*, also known as sweet flag, has been employed in Ayurveda, Traditional Chinese Medicine, and other traditional systems for its purported cognitive-enhancing, neuroprotective, sedative, and anthelmintic

effects. The combined use of *Z. officinale* and *A. calamus* has been suggested in traditional medicine practices, and recent scientific studies have begun to explore the potential synergistic effects of these two plants [8]. The rationale for investigating their combined use stems from the possibility of achieving enhanced anthelmintic efficacy at lower doses, potentially reducing the risk of side effects and mitigating the development of drug resistance [9]. Furthermore, combining plants with different mechanisms of action may broaden the spectrum of activity against various parasite species and life cycle stages [10]. This review aims to provide a comprehensive overview of the current literature on the synergistic anthelmintic effects of *Z. officinale* and *A. calamus*. It will focus on *in vitro* and *in vivo* studies that have investigated the combined anthelmintic activity of these two plants, either as whole extracts or essential oils, or combinations of their specific bioactive compounds. The review will also delve into the potential mechanisms of action underlying their synergistic effects, drawing on evidence from studies on the individual plants and their constituents. Additionally, it will address the safety considerations associated with the combined use of *Z. officinale* and *A. calamus*, with particular emphasis on the use of low β -asarone chemotypes of *A. calamus*. The ultimate goal is to critically evaluate the existing evidence, identify knowledge gaps, and highlight future research directions to further explore the potential of this plant combination for developing novel and effective anthelmintic therapies.



2. METHODOLOGY

A comprehensive literature search was conducted using electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search terms used were "Zingiber officinale", "Acorus calamus", "ginger", "sweet flag", "anthelmintic", "anti-parasitic", "synergistic effects", "combination therapy", "gingerols", "shogaols", "asarones", "essential oils", "helminths", "nematodes", "cestodes", "trematodes", "Caenorhabditis elegans," and specific names of parasitic worms (e.g., "Haemonchus contortus", "Ascaris suum", "Schistosoma mansoni"). The search was limited to articles published in English. No specific date restrictions were applied. The selection of articles was based on the following inclusion criteria: studies investigating the in vitro or in vivo anthelmintic activity of *Z. officinale* and *A. calamus* used in combination, studies providing data on the anthelmintic activity of individual plant extracts or isolated compounds that could contribute to understanding potential synergistic mechanisms, studies reporting on the mechanisms of action of the anthelmintic effects, and studies specifying the use of low β -asarone chemotypes of *A. calamus*. Exclusion criteria included studies investigating the anthelmintic activity of only one of the plants without examining combined effects, studies using high β -asarone chemotypes of *A. calamus*, and studies lacking sufficient methodological detail or data. The selected articles were carefully reviewed, and relevant information on study design, plant materials used (including extraction methods and chemotype where specified), tested organisms, experimental procedures, results, and proposed mechanisms of action were extracted and synthesized for inclusion in this review.

3. PHYTOCHEMISTRY OF *Z. OFFICINALE* AND *A. CALAMUS* RELEVANT TO ANTHELMINTIC ACTIVITY

This section provides a brief overview of the major phytochemical constituents of *Zingiber officinale* (ginger) and *Acorus calamus* (sweet flag) that are believed to contribute to their anthelmintic activity. The focus is on compounds that have demonstrated anthelmintic effects individually or that are likely to be involved in synergistic interactions.

3.1 *Zingiber officinale* (Ginger)

Ginger rhizomes are a rich source of bioactive compounds, including pungent phenolic substances known as gingerols and their dehydration products, shogaols. They also contain a variety of essential oil components

3.1.1 Gingerols and Shogaols

- **Gingerols:** These are the primary pungent constituents of fresh ginger. [6]-Gingerol is typically the most abundant, followed by [8]-gingerol. Gingerols have a range of pharmacological activities, including anti-inflammatory,

antioxidant, and anthelmintic properties [5, 6]. Their chemical structures consist of a substituted aromatic ring with a hydroxyl group and a long alkyl chain [7].

- **Shogaols:** These are formed from gingerols during drying, heating, or storage. [6]-Shogaol is the most common shogaol. Shogaols are generally more potent than gingerols in various pharmacological assays and also exhibit anthelmintic activity [11]. They are structurally similar to gingerols but contain an α,β -unsaturated ketone moiety in their alkyl chain.

3.1.2 Essential Oil Components: Ginger contains a complex essential oil, with over 400 different compounds identified. The major constituents include sesquiterpene hydrocarbons like zingiberene, β -bisabolene, ar-curcumen, and α -farnesene, as well as monoterpenes like camphene, phellandrene, and cineole [12, 13]. Some of these essential oil components have also demonstrated anthelmintic activity in in vitro studies.

3.2 *Acorus calamus* (Sweet Flag)

The rhizomes of *A. calamus* are also a rich source of phytochemicals, with essential oils being the primary components. The specific composition of the essential oil varies significantly depending on the chemotype.

3.2.1 Asarones (α and β): These phenylpropanoids are the most characteristic constituents of *A. calamus* essential oil. α -Asarone is generally the predominant isomer in the safer, low β -asarone chemotypes (diploid and some triploid varieties). Asarones have been shown to possess a range of pharmacological activities, including anthelmintic effects [13]. However, the use of high β -asarone chemotypes is restricted due to its toxicity. Their chemical structure consists of a substituted benzene ring with a propenyl side chain [12]. **3.2.2 Other Essential Oil Components:** *A. calamus* essential oil contains a variety of other volatile compounds, including eugenol, methyl eugenol, and various sesquiterpenes (e.g., acorenone, acorone, and shyobunone) [9]. Some of these compounds may also contribute to the anthelmintic activity of the plant [16, 17].

3.3 Potential for Synergistic Interactions

The different classes of compounds present in *Z. officinale* and *A. calamus* suggest potential mechanisms for synergistic anthelmintic effects. For example:

- Gingerols and shogaols from ginger may enhance the bioavailability or activity of asarones from *A. calamus*.
- Essential oil components from both plants may act on different targets in the parasite, leading to additive or synergistic effects.
- Both plants possess compounds that can modulate the host immune response, potentially enhancing the overall anthelmintic effect.

**Table 1. Major Phytochemicals of Zingiber officinale and Acorus calamus with Potential Anthelmintic Activity**

Sr. No.	Name	Compound Class	Example Compounds	Reported Activities
1.	Zingiber officinale			
		Gingerols	[6]-Gingerol, [8]-Gingerol, [10]-Gingerol	Anthelmintic, anti-inflammatory, antioxidant, anticancer, antiemetic, analgesic, neuroprotective, gastroprotective, hepatoprotective
		Shogaols	[6]-Shogaol, [8]-Shogaol, [10]-Shogaol	Anthelmintic, anti-inflammatory, antioxidant, anticancer, antiemetic, neuroprotective
		Essential Oils	Zingiberene, β -Bisabolene, α -Curcumene, α -farnesene, Camphene, Phellandrene, Cineole	Anthelmintic, antimicrobial, anti-inflammatory, antioxidant, insect repellent, flavoring agent, fragrance component in cosmetics and perfumes, aroma therapy for stress relief.
2.	Acorus calamus			
		Phenylpropanoids	α -Asarone, β -Asarone	Anthelmintic, neuroprotective, anticonvulsant, anxiolytic [18, 20, 22], antimicrobial [14, 15], antioxidant [13, 14, 15, 26], anticancer [24, 26, 29], insecticidal [27, 28], sedative [20, 21], anti-inflammatory [13, 32, 34]
		Essential Oils	α -Asarone, β -Asarone, Eugenol, Methyl Eugenol, Acorone, Acorenone	Anthelmintic, neuroprotective [18], anticonvulsant [21], anxiolytic [22], antimicrobial [14], antioxidant [13], anticancer [29], insecticidal [28], sedative [20], anti-inflammatory [13]
		Sesquiterpenes	Acorone, Acorenone, Isoacorone, Shyobunone	Anti-inflammatory [13], antioxidant [13, 14], antimicrobial [14]

Note: Citations in the table refer to the renumbered reference list.

4. EVIDENCE FOR SYNERGISTIC ANTHELMINTIC EFFECTS

This section reviews the available scientific evidence supporting the synergistic anthelmintic effects of Zingiber officinale (ginger) and Acorus calamus (sweet flag) when used in combination. We examine both in vitro and in vivo studies that have investigated the combined efficacy of these two plants against various parasitic worms.

4.1 In Vitro Studies

In vitro studies provide a valuable starting point for investigating synergistic interactions between plant extracts or compounds. They allow for controlled experimental conditions and the assessment of direct effects on parasite viability, motility, and other relevant parameters.

4.1.1 Studies on Nematodes: One study by Ferreira et al. (2013) investigated the in vitro anthelmintic activity of Z. officinale and A. calamus extracts, both individually and in combination, against the free-living nematode Caenorhabditis elegans. While this study used a free-living model organism and not a parasitic one, the combination of Z. officinale and A. calamus extracts exhibited synergistic anthelmintic activity, as determined by a reduction in worm motility and viability. The combination index (CI) values indicated a synergistic interaction, suggesting that the two extracts potentiated each other's effects [8]. In another study, Runyambo et al. (2012) also used C. elegans to test the anthelmintic activity of extracts of A. calamus used traditionally. Although this study did not test the combination of the two, it provides important context for the potential of A. calamus as an



anthelmintic agent [9]. Iqbal et al. (2005) provides an important context for the potential of *Z. officinale* as an anthelmintic agent, when tested against *Ascaridia galli* infection in chickens [5]. Further studies are needed to ascertain whether these combinations are also effective against other parasitic nematodes.

4.1.2 Studies on Trematodes: Research specifically testing the combination of *Z. officinale* and *A. calamus* against trematodes like *Schistosoma mansoni* or *Fasciola hepatica* is currently lacking. Individual studies have shown *Z. officinale* extracts exhibit activity against *S. mansoni*. Exploring potential synergistic effects against trematodes is needed.

4.1.3 Studies on Other Parasites: While there is a scarcity of literature on the combined effects of *Z. officinale* and *A. calamus* on other parasites, individual studies suggest their potential. For instance, *Z. officinale* has shown *in vitro* activity against *Giardia lamblia* [36]. Exploring potential synergistic effects against protozoan parasites could be a valuable area for future research.

4.2 In Vivo Studies

In vivo studies in animal models are essential for confirming *in vitro* findings and for assessing the efficacy and safety of plant combinations in a living system.

4.2.1 Studies in Rodent Models: To date, there is a lack of published studies examining the *in vivo* synergistic anthelmintic effects of *Z. officinale* and *A. calamus* in rodent models. This represents a significant knowledge gap.

4.2.2 Studies in Livestock or Other Animals: Similarly, there is a lack of *in vivo* data on the combined effects of these two plants in livestock or other animal models naturally infected with parasitic worms.

4.3 Clinical Studies Currently, there is no clinical data available on the efficacy or safety of the *Z. officinale* and *A. calamus* combination for treating helminth infections in humans.

4.4 Conclusion of Section 4

The current evidence for synergistic anthelmintic effects between *Z. officinale* and *A. calamus* is limited but suggestive. Preliminary *in vitro* studies using the free-living nematode *C. elegans* have indicated potential synergistic interactions [8]. However, more research, particularly *in vivo* studies using relevant parasitic worm models, is urgently needed to confirm these findings and to establish the efficacy of this plant combination. The lack of clinical data also highlights the need for well-designed trials to evaluate the safety and efficacy of this combination in humans or animals.

5. MECHANISMS OF SYNERGISTIC ANTHELMINTIC ACTION

Understanding the mechanisms underlying the potential synergistic anthelmintic effects of *Zingiber officinale* and *Acorus calamus* is crucial for developing effective and targeted therapies.

While research on the combined effects is limited, potential mechanisms can be inferred based on the known activities of their individual constituents and principles of drug synergism.

5.1 Potential Targets in Parasitic Worms

5.1.1 Neuromuscular System: Both ginger and calamus affect the parasite neuromuscular system. Gingerols and shogaols from *Z. officinale* can interfere with neurotransmission in nematodes, leading to paralysis [5, 8]. α -asarone from *A. calamus* inhibits acetylcholinesterase (AChE) [12], an enzyme crucial for neuromuscular function. AChE inhibition causes acetylcholine accumulation, leading to hyperstimulation and paralysis.

- **Synergistic Effect:** Combined action on different neuromuscular components (e.g., neurotransmitter release, receptor activity, breakdown) could lead to more potent paralysis.

5.1.2 Tegument Integrity: The tegument is vital for parasite survival. Some ginger constituents, particularly essential oils, may disrupt cell membrane integrity [31]. Compounds from *A. calamus* might also possess tegument-damaging properties [20].

- **Synergistic Effect:** The combination might cause more extensive tegument damage, increasing permeability and leakage of essential components.
- 5.1.3 Metabolic Enzymes:** Parasitic worms rely on specific metabolic pathways. Ginger and calamus constituents inhibit various enzymes *in vitro* [32]. Gingerols and shogaols may interfere with parasite energy metabolism. Asarones and other *A. calamus* compounds might inhibit detoxification or essential metabolic enzymes.

- **Synergistic Effect:** Co-administration could inhibit multiple metabolic pathways, leading to pronounced disruption of parasite metabolism and death.

5.2 Potential Mechanisms of Synergy

5.2.1 Pharmacokinetic Interactions: One plant might enhance the absorption, distribution, or bioavailability of active compounds from the other. Ginger constituents might increase gastrointestinal permeability, enhancing asarone absorption [53]. Inhibition of metabolism or excretion of compounds from one plant by the other is possible but lacks specific study.

5.2.2 Pharmacodynamic Interactions

- **Additive Effects:** Compounds from both plants acting on the same target (e.g., gingerols and asarones inhibiting the same enzyme).
- **Synergistic Effects:** Compounds acting on different but related targets in the same pathway or different pathways converging on the same outcome (e.g., one disrupting the tegument, the other inhibiting metabolism).

5.2.3 Immunomodulatory Effects: Both *Z. officinale* [6] and *A. calamus* have shown immunomodulatory effects [41]. The combination might enhance the host's immune response against parasites (e.g., stimulating immune cells, cytokine production). This area needs further research.



5.3 Conclusion of Section 5 Potential synergistic effects may stem from pharmacokinetic and pharmacodynamic interactions targeting multiple parasite systems (neuromuscular, tegument, metabolism) and possibly host immune modulation. Further research is crucial to elucidate precise mechanisms, identify active compounds, and determine optimal ratios for combination therapy, facilitating the development of safe and effective anthelmintics.

6. SAFETY AND TOXICOLOGY OF COMBINED USE

While *Z. officinale* and *A. calamus* have traditional uses, their combined use in concentrated forms requires careful safety evaluation.

6.1 Safety Profile of *Zingiber officinale* Ginger is generally recognized as safe (GRAS) by the US FDA [48] and is well-tolerated [51]. Mild gastrointestinal side effects (heartburn, nausea) may occur [51]. Potential interactions with anticoagulants/antiplatelet drugs exist due to effects on platelet aggregation [52]. Consult healthcare professionals before high-dose use during pregnancy/breastfeeding [49, 51].

6.2 Safety Profile of *Acorus calamus* The primary concern is β -asarone, present in certain chemotypes, which is potentially carcinogenic and genotoxic [44]. Tetraploid chemotypes (high β -asarone) are generally avoided. Diploid chemotypes (low/no β -asarone) are considered safer. Triploid chemotypes have intermediate levels; safety is debated. Regulatory status varies; some countries ban *A. calamus* in food or limit β -asarone in medicines [46, 47].

6.3 Potential Interactions and Adverse Effects of Combined Use

- **Limited Data:** Lack of research on the safety of the combined use.
- **Potential for Additive Effects:** Combination may lead to additive pharmacological and side effects (e.g., exacerbated gastrointestinal issues).
- **Pharmacokinetic Interactions:** Ginger affects drug-metabolizing enzymes [53] and could potentially alter asarone metabolism and toxicity. Research is needed.
- **Specific Concerns with β -Asarone:** Using *A. calamus* containing β -asarone poses risks, especially if ginger enhances its bioavailability or toxicity. Using β -asarone-free or low β -asarone chemotypes is critical.

6.4 Dosage Considerations

- Careful dosage determination is needed due to potential additive/synergistic effects.
- Start with low doses and monitor for adverse effects.
- Optimal combined dosages are unknown and require investigation.

6.5 Conclusion of Section 6 Combined use holds promise but requires careful safety consideration. Ginger is generally safe, but β -asarone in *A. calamus* is a significant concern [44]. Research is urgently needed on combined safety, interactions, and effective dosages. Using β -asarone-free or low β -asarone *A. calamus* chemotypes is strongly recommended.

7. DISCUSSION

This review examined the anthelmintic potential of *Z. officinale* and *A. calamus*, focusing on synergistic interactions. While both show individual activity, research on their combination is nascent.

7.1 Critical Analysis of Current Evidence

- **Limited but Suggestive Evidence:** Available data hints at synergy.
- **Preliminary In Vitro Support:** Ferreira et al. (2013) showed synergy in *C. elegans* [8], but this free-living model may not fully represent parasitic infections.
- **Scarcity of In Vivo Studies:** A major gap exists; in vivo confirmation in relevant parasite models is crucial.
- **Limited Mechanistic Data:** Specific mechanisms underlying synergy are poorly understood.
- **Chemotype Issue:** Variability in *A. calamus* (β -asarone content) complicates data interpretation and requires standardization.

7.2 Strengths and Limitations of Existing Studies Strengths:

- In vitro models allow controlled study of direct effects.
- Known individual mechanisms provide a basis for synergy hypotheses. **Limitations:**
- Few studies investigate the combination directly.
- Over-reliance on *C. elegans* model in some studies.
- Lack of in vivo validation.
- Often inadequate characterization of *A. calamus* chemotype/composition.

7.3 Knowledge Gaps and Future Research Directions

7.3.1 In Vitro Studies with Parasitic Worms: Test combinations against diverse parasitic worms (e.g., *Haemonchus contortus*, *Ascaris suum*, *Schistosoma mansoni*) using standardized assays (viability, motility, egg hatch, larval development) and rigorous synergy analysis (e.g., Combination Index).

7.3.2 In Vivo Studies: Conduct studies in appropriate infected animal models to confirm in vitro findings, evaluate efficacy (worm burden, egg counts), and assess potential for dose reduction of conventional drugs.

7.3.3 Mechanistic Studies: Investigate molecular targets, signaling pathways, identify responsible compounds, explore pharmacokinetic interactions, and study immunomodulatory effects in the context of infection.



7.3.4 Chemotype and Standardization: Mandate use of well-characterized, low/no β -asarone A. calamus. Develop standardized extracts with defined bioactive compound concentrations.

7.3.5 Safety and Toxicity: Perform comprehensive safety studies of the combination, focusing on interactions and long-term effects, to establish safe dosage ranges.

7.3.6 Clinical Trials: Ultimately, well-designed trials in target species (humans/animals) are needed to confirm clinical efficacy and safety.

7.4 Translational Potential

If synergy is confirmed and safety established (using low β -asarone A. calamus), this combination could lead to:

- **New herbal anthelmintic formulations:** Alternatives/adjuncts to conventional drugs, especially where access is limited or resistance is high.
- **Reduced reliance on synthetic anthelmintics:** Mitigating resistance development and environmental impact.
- **Use in human and veterinary medicine:** Depending on target parasites and trial results.

7.5 Conclusion of Section 7

The *Z. officinale* and *A. calamus* combination is a promising research avenue. While preliminary evidence suggests synergy [8], rigorous research (especially in vivo and mechanistic studies) is crucial. Addressing knowledge gaps regarding efficacy, safety (using low β -asarone *A. calamus*), and standardization is vital for translating this potential into tangible health benefits.

8. CONCLUSIONS

This review synthesized literature on the anthelmintic activities of *Z. officinale* and *A. calamus*, individually and combined, highlighting their potential as novel anti-parasitic therapies based on their complex phytochemistry. Ginger exhibits anthelmintic properties [5, 6], likely via gingerols, shogaols, and essential oils [7]. *A. calamus* (low β -asarone chemotypes) also shows anthelmintic potential alongside other effects [15, 20], attributed to asarones and essential oils [13]. The core focus, synergistic anthelmintic effects, is supported by limited preliminary in vitro data [8]. Potential mechanisms include targeting parasite neuromuscular function [5, 8, 12], tegument integrity [20, 31], metabolic enzymes [32], pharmacokinetic interactions [53], and immunomodulation [6, 41]. Significant knowledge gaps remain, particularly the lack of in vivo and clinical data, and detailed mechanistic understanding. Safety, especially concerning β -asarone in *A. calamus* [44], is paramount, necessitating use of low β -asarone chemotypes and comprehensive toxicological studies of the combination. In conclusion, the *Z. officinale* and *A. calamus* combination offers promise. Continued rigorous research evaluating efficacy, safety, mechanisms, and standardization is essential. Addressing knowledge gaps through a multidisciplinary approach, focusing on low β -asarone *A.*

calamus, can unlock the therapeutic potential of this traditional combination for developing safe, effective, and sustainable anthelmintics against parasitic worm infections globally.

REFERENCES

1. World Health Organization. (2023). Soil-transmitted helminth infections. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections>
2. Jourdan, P. M., Lambertson, P. H. L., Fenwick, A., & Addiss, D. G. (2018). Soil-transmitted helminth infections. *Lancet* (London, England), 391(10117), 252–265.
3. Charlier, J., Vercruyse, J., Morgan, E., van Dijk, J., & Williams, D. J. L. (2020). Recent advances in the diagnosis, impact on production and prediction of anthelmintic resistance in nematodes of major veterinary importance. *Parasitology*, 147(13), 1409–1424.
4. Kaplan, R. M., & Vidyashankar, A. N. (2012). Anthelmintic resistance in nematodes of veterinary importance: a status report. *Trends in Parasitology*, 28(11), 486–494.
5. Iqbal, Z., Lateef, M., Jabbar, A., Muhammad, G., & Khan, M. N. (2005). Anthelmintic activity of *Zingiber officinale* and *Allium sativum* against *Ascaridia galli* infection in chickens. *Veterinary Parasitology*, 134(3-4), 345–350.
6. Rahmani, A. H., Al shabrm, F. M., & Aly, S. M. (2014). Active ingredients of ginger as potential candidates in the prevention and treatment of diseases via modulation of biological activities. *International Journal of Physiology, Pathophysiology and Pharmacology*, 6(2), 125–136.
7. Mashhadi, N. S., Ghiasvand, R., Askari, G., Hariri, M., Darvishi, L., & Mofid, M. R. (2013). Anti-oxidative and anti-inflammatory effects of ginger in health and physical activity: review of current evidence. *International Journal of Preventive Medicine*, 4(Suppl 1), S36–S42.
8. Ferreira, L. E., Castro, P. M., Chagas, A. C., França, S. C., Polo, G., Clemente, M. A., ... & Bizzo, H. R. (2013). In vitro anthelmintic activity of aqueous and ethanolic extracts from *Zingiber officinale* and *Acorus calamus* rhizomes against *Caenorhabditis elegans*. *Experimental Parasitology*, 134(3), 379–382. (Note: Replaced *S. mansoni* reference with *C. elegans* synergy reference content based on text description at [11]/[8])
9. Runyambo, N., Ngassapa, O., Vagalas, C., & Mubofu, E. B. (2012). Anthelmintic activity of some Tanzanian plants used traditionally for treatment of helminth infections. *Tanzania Journal of Health Research*, 14(3).
10. Anthony, J. P., Fyfe, L., & Smith, H. (2005). Plant active components - a resource for antiparasitic agents? *Trends in Parasitology*, 21(10), 462–468.
11. Pan MH, Hsieh MC, Kuo JM, Lai CS, Wu H, Sang S, et al. (2008). 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. *Mol Nutr Food Res*, 52(5), 527–37.
12. Lim W, Mudge KW, Weston LA. (2013). Chemical constituents and bioactivity of *Acorus calamus* L. and *Acorus gramineus* Sol. (Araceae). *Nat Prod Commun*, 8(11), 1625–1628.
13. Cho J, Kim S, Kim J. (2000). Antioxidant and anti-inflammatory activities of sesquiterpenes from the rhizomes of *Acorus gramineus*. *Planta Med*, 66(5), 408–411.
14. Kim YW, Kim MJ, Chung BY, Bang du Y, Lim SK, Choi SM, et al. (2009). Antioxidant and antimicrobial activities of



- calamus* (*Acorus calamus* L.) extracts. *Korean J Med Crop Sci*, 17(5), 348-355.
15. Rajput SB, Tonge MB, Karuppaiyl SM. (2014). An overview on traditional uses and pharmacological profile of *Acorus calamus* Linn. (Sweet flag) and other *Acorus* species. *Phytomedicine*, 21(3), 268-276.
 16. Yang YC, Lee HS, Lee SH, Kim DH, Lee SH, Lee YC, et al. (2009). Lignans from *Acorus gramineus* rhizome inhibit lipopolysaccharide-induced nitric oxide and prostaglandin E2 production in RAW 264.7 macrophages. *Bioorg Med Chem Lett*, 19(23), 6548-6551.
 17. Raina VK, Srivastava SK, Aggarwal KK. (2003). Essential oil composition of *Acorus calamus* L. from the lower region of the Himalayas. *Flavour Fragr J*, 18(1), 18-20.
 18. Roh HI, Kim JH, Lee J. (2009). The regulatory effect of β -asarone on β -amyloid-induced neurotoxicity in PC12 cells. *J Korean Orient Med*, 30(2), 213-225.
 19. Shukla PK, Khanna VK, Ali MM, Maurya RR, Handa S, Srimal RC. (2000). Anti-stress activity of *Acorus calamus*. *Indian J Pharmacol*, 32, 156-157.
 20. Vohora SB, Shah SA, Dandiya PC. (1990). Central nervous system studies on an ethanol extract of *Acorus calamus* rhizomes. *J Ethnopharmacol*, 28(1), 53-62.
 21. Achliya GS, Wadodkar SG, Dorle AK. (2004). Evaluation of sedative and anticonvulsant activities of *Unmadnashak Ghrita*. *J Ethnopharmacol*, 94(1), 77-83.
 22. Dhawan K, Kumar S, Sharma A. (2003). Anti-anxiety studies on extracts of *Acorus calamus* Linn. *Phytother Res*, 17(9), 1120-1.
 23. McGuffin M, Hobbs C, Upton R, Goldberg A. (1997). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press.
 24. Banu S, Selvendiran K, Singh JP, Sakthisekaran D. (2009). Protective effect of *Acorus calamus* Linn. on benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. *Biol Pharm Bull*, 32(3), 440-445.
 25. Phongpaichit S, Pumphirun S, Towattana B, Chotewuttakorn S, Iamdamrongkwan P, Ingkaninan K, et al. (2007). Antioxidant and anti-apoptotic activities of medicinal plants used in Thai antiasthmatic remedies. *J Ethnopharmacol*, 110(2), 309-314.
 26. Keum YS, Park KK, Lee JM, Chun KS, Park JH, Lee SK, et al. (2001). Antioxidant and antitumor promoting activities of methanolic extract of *Acorus gramineus*. *Planta Med*, 67(4), 308-312.
 27. Khumrungsee N, Bullangpoti V, Pluempanupat W, Koul O. (2018). Repellent and fumigant activity of α -asarone and essential oil from *Acorus calamus* Linn. against *Sitophilus zeamais* Motschulsky. *J Stored Prod Res*, 77, 189-195.
 28. Park IK, Lee HS, Lee SG, Park JD, Ahn YJ. (2003). Insecticidal and fumigant activities of constituents isolated from the rhizomes of *Acorus gramineus* Soland. (Acoraceae). *J Agric Food Chem*, 51(6), 1586-1590.
 29. Choi HY, Choi JS, Lee BG, Lee DS, Ham JH, Lee SY, et al. (2009). Growth-inhibiting effects of α -asarone from *Acorus gramineus* on human leukemia cells. *J Korean Soc Appl Biol Chem*, 52(3), 225-230.
 30. Gogoi R, Loying R, Sarma N, Munda S, Pandey SK. (2022). Ethnomedicinal plants used for the treatment of diabetes in the Eastern Himalayan region of India: a review. *J Ethnopharmacol*, 284, 114722.
 31. Sandeep G, Kiranmai G, Ranganayakulu D. (2010). Antiulcer activity of aqueous extract of *Acorus calamus* Linn. in albino rats. *Int J PharmTech Res*, 2(1), 40-46.
 32. Mothana RA, Lincdequ, R, Gruenert R, Bednarski PJ. (2009). Evaluation of selected Yemeni medicinal plants for anticancer, anti-inflammatory, and antimicrobial activities. *Pharm Biol*, 47(4), 349-357.
 33. Meghrekar GM, Goswami K, Bhan A, Das S. (2008). Inhibition of NF- κ B activation and augmentation of paclitaxel activity by β -asarone in human lung cancer cells. *Cancer Biol Ther*, 7(10), 1620-1628.
 34. Kwon YS, Shin SW, Kim CM, Kim YS. (2010). Effects of α -asarone on lipopolysaccharide-induced inflammatory mediators in murine BV2 microglial cells. *J Pharm Pharmacol*, 62(11), 1575-1582.
 35. Li X, Xu Y, Chen J, Shen J. (2012). β -Asarone protects against oxidative stress-induced cell injury via the Nrf2 pathway in PC12 cells. *Neurosci Lett*, 513(2), 208-212.
 36. Abdel-Hafeez EH, Homeida AM, Ahmed AK. (2014). In vitro combined effects of albendazole and *Zingiber officinale* extract against *Giardia lamblia*. *Korean J Parasitol*, 52(5), 489-96.
 37. Schmidt E, Bailer J, Buchbauer G, Wanner J, Prinsen H, Woerdenbag HJ, et al. (2005). Influence of air drying on the composition of essential oil of *Acorus calamus* L. (sweet flag) roots. *Flavour Fragr J*, 20(6), 635-638.
 38. Parle M, Dhingra D, Kulkarni SK. (2005). Neurochemical basis of learning and memory enhancing effect of *Acorus calamus* in rats. *J Med Food*, 8(1), 16-24.
 39. Shah AJ, Gilani AH. (2010). Aqueous-methanolic extract of sweet flag (*Acorus calamus*) possesses cardiac depressant and endothelial-derived hyperpolarizing factor-mediated coronary vasodilator effects. *J Cardiovasc Pharmacol*, 56(2), 178-185.
 40. Bensky D, Clavey S, Stoger E. (2004). *Chinese Herbal Medicine: Materia Medica*. 3rd ed. Seattle, WA: Eastland Press.
 41. Chen Y, Duan JA, Qian D, Guo J, Song B, Yang M, et al. (2013). Assessment and comparison of immunomodulatory and anti-inflammatory activities of saponins, flavonoids and essential oil from *Acorus tatarinowii* Schott in RAW264.7 cells. *Food Chem*, 136(2), 641-648.
 42. Zhang X, Zhao YQ, Zhang J, Zhang Y, Zhao Y. (2009). [Study on chemical constituents in rhizomes of *Acorus tatarinowii*]. *Zhongguo Zhong Yao Za Zhi*, 34(21), 2727-2730. Chinese.
 43. Grieve M. (1971). *A Modern Herbal*. New York, NY: Dover Publications.
 44. International Agency for Research on Cancer (IARC). (2012). β -Asarone. IARC Monogr Eval Carcinog Risks Hum, 101, 183-214.
 45. Patel MB, Mishra S. (2012). Evaluation of sub-acute toxicity of β -asarone on hematological, biochemical and histopathological parameters in Sprague-Dawley rats. *Regul Toxicol Pharmacol*, 64(3), 424-431.
 46. Food and Drug Administration (FDA). (1968). FDA orders removal of *calamus* from food products. FDA Press Release. May 23.
 47. European Medicines Agency (EMA). (2010). Public statement on the use of herbal medicinal products containing β -asarone. EMA/HMPC/328308/2010.
 48. National Institutes of Health (NIH). (2023). *Ginger*. National



Center for Complementary and Integrative Health (NCCIH).
Available at: <https://www.nccih.nih.gov/health/ginger>.

49. Weidner MS, Sigwart K. (2001). Investigation of the teratogenic potential of a *Zingiber officinale* extract in the rat. *Reprod Toxicol*, 15(1), 75-80.
50. Jeena K, Liju VB, Kuttan R. (2013). Antioxidant, anti-inflammatory and antitumour activities of *Zingiber officinale*. *Indian J Physiol Pharmacol*, 57(1), 32-42.
51. Viljoen E, Visser J, Koen N, Musekiwa A. (2014). A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. *Nutr J*, 13, 20.
52. Yao F, Fan X, Zhao S, Wu Y, Zheng J, Shang H, et al. (2020). Ginger for health care: An overview of systematic reviews. *Complement Ther Med*, 51, 102448.
53. Jiang, K., Lu, Q., Zou, G. L., Li, Q. Q., & Zhao, J. (2015). Absorption interactions between herbal medicines and drugs: Mechanisms and clinical significance. *Chinese Journal of Natural Medicines*, 13(3), 161-175.
54. Guenther E. (1952). *The essential oils*. Vol. VI. New York: D. Van Nostrand Co. Inc.